MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, UNCY had $20,368K increase in cash & cash equivalents over the period. -$5,964K in free cash flow.

Cash Flow Overview

Change in Cash
$20,368K
Free Cash flow
-$5,964K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-6,010 -5,877
Depreciation expense
10 14
Stock-based compensation expense
730 1,134
Change in fair value of warrant liability
-1,067 -8,722
Amortization of operating lease right of use asset
138 259
Prepaid expense and other current assets
394 2,392
Accounts payable and accrued liabilities
775 -1,466
Operating lease liability
-144 -273
Net cash used in operating activities
-5,962 -17,323
Proceeds from issuance of series b-1 preferred stock
-0
Purchases of property and equipment
2 22
Dividends on preferred stock
-0
Net cash used in investing activities
-2 -22
Proceeds from secondary public offering
27,147 12,624
Issuance costs related to issuance of series b-1 preferred stock
-0
Commissions paid on secondary public offering
814 379
Payments on financed insurance policies
1 211
Proceeds from exercise of warrants
0 1,496
Net cash provided by financing activities
26,332 13,530
Net increase in cash and cash equivalents
20,368 -3,815
Cash and cash equivalents at beginning of period
26,142 -
Cash and cash equivalents at end of period
42,695 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Unicycive Therapeutics, Inc. (UNCY)

Unicycive Therapeutics, Inc. (UNCY)